In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Funding Options for European biotech

Executive Summary

The flotation of UK biotech Ark Therapeutics, likely followed closely by Switzerland's Basilea, suggest Europe's public markets are waking up. It's too early, as yet, to call the IPO window open, though. And the string of European hopefuls monitoring Ark's progress and hoping to follow in its wake will have to contend with investors who are far more discerning than during the last upturn. Late-stage products remain attractive, but there are few fixed rules.

You may also be interested in...



Sinclair Pharma: How Low Risk Can You Go?

Sinclair Pharma was the only health care firm to have floated in Europe in 2003; investors liked its very low risk model: take little development risk then partner for marketing. Yet in taking the specialty model to its extreme, Sinclair's challenge will be to secure enough valuable products to keep investors interested, particularly if European markets warm up and begin to embrace a new, stronger generation of R&D focused firms.

Biotech or Bank?

A look at twenty European biotech companies' cash holdings as a percentage of their market values. Thanks to strengthening investor sentiment in European biotech, certain firms are enjoying bumper years, while others continue to slump with market caps below the value of their cash holdings.

Biotech or Bank?

A look at twenty European biotech companies' cash holdings as a percentage of their market values. Thanks to strengthening investor sentiment in European biotech, certain firms are enjoying bumper years, while others continue to slump with market caps below the value of their cash holdings.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel